Latest News

SLEEP 2026: In an 8-week randomized trial, reishi mushroom extract reduced Insomnia Severity Index scores more than melatonin in adults with chronic insomnia.

Prenatal sleep expectations predicted postpartum sleep quality above parity and psychiatric history, with postpartum anxiety further worsening outcomes.

High-risk rural patients were less likely than urban patients to be referred for obstructive sleep apnea evaluation in primary care.

New research suggests EDS combined with prolonged sleep-onset latency is linked to 3x greater risk of incident hypertension and 2x greater risk of prevalent hypertension.

The EEG-guided MeRT system is the first personalized, biomarker-guided neuromodulation technology to receive FDA clearance for PTSD.

AD109 reduced apnea-hypopnea index versus placebo in a phase 3 trial of adults with OSA unable or unwilling to use CPAP.

Takeda reported phase 3 data showing zasocitinib achieved higher week 16 PASI 100 responses than deucravacitinib in plaque psoriasis.

Late-breaking SLEEP 2026 findings bring primary-care-ready insights on insomnia drugs, sleep apnea genetics, menopausal sleep, and GLP-1 links.